Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | AB154 |
Trade Name | |
Synonyms | AB-154|AB 154|Domvanalimab |
Drug Descriptions |
AB154 (domvanalimab) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A124). |
DrugClasses | Immune Checkpoint Inhibitor 147 TIGIT Antibody 14 |
CAS Registry Number | NA |
NCIT ID | C162875 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AB154 | AB154 | 0 | 2 |
AB154 + AB928 + Zimberelimab | AB154 AB928 Zimberelimab | 0 | 2 |
AB154 + APX005M + Zimberelimab | AB154 APX005M Zimberelimab | 0 | 1 |
AB154 + Durvalumab | AB154 Durvalumab | 0 | 1 |
AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | AB154 Fluorouracil Leucovorin Oxaliplatin Zimberelimab | 0 | 1 |
AB154 + Zimberelimab | AB154 Zimberelimab | 0 | 5 |